L’article Dr Bonnefoy to inaugurate first CyTOF Hyperion in France est apparu en premier sur Orega Biotech.

Read the full manuscript titled “Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies”

L’article Anti-CD39 mAb publication in Cell Reports est apparu en premier sur Orega Biotech.

L’article Meet us at the 2019 ASCO annual meeting in Chicago est apparu en premier sur Orega Biotech.

L’article Meet us at the 2018 Bio Europe meeting in Copenhagen est apparu en premier sur Orega Biotech.

Lyon, October 8, 2018

Interleukin-17 patent granted in Europe

Lyon, France, October 8, 2018 – OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced the grant of patent EP2569335 by the European Patent Office. This patent covers IL-17A neutralizing antibodies for use as a therapeutic tool to increase the response to other chemotherapeutic agents. “The delivery of this European Patent is another important milestone for OREGA Biotech; it is the fifth issued patent related to our IL‑17 programs”, commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech. “Intellectual property is a key asset in OREGA’s target discovery programs. Our capacity to obtain broad claims covering novel cancer targets offers a valuable competitive advantage.”

Read the press release.

L’article PRESS RELEASE – IL-17 patent granted in Europe est apparu en premier sur Orega Biotech.

L’article AstraZeneca and Innate Pharma enter into partnership for the development of CD39 mAbs est apparu en premier sur Orega Biotech.

L’article Meet us at the 2018 Bio Convention to be held in Boston est apparu en premier sur Orega Biotech.

SESSION PO.IM02.06 – Cytokines: The First Modern Immunotherapies

April 3, 2017, 8:00 AM – 12:00 PM

1602 / 10 – Generation of anti-IL-17B antibodies neutralizing IL-17B-mediated alterations of the immune microenvironment, promotion of tumor cell initiating capacity and chemoresistance

L’article IL-17B program to be presented at AACR 2017 est apparu en premier sur Orega Biotech.

Lyon, France, April 18, 2017 –  OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced today that it has received a notification of allowance from the USPTO stating its intention to grant a patent application filed by OREGA Biotech and related to novel anti-IL-17 antibodies. This patent covers antibodies binding to a functional epitope of IL-17 identified by OREGA Biotech and protects several specific neutralizing antibodies able to bind and inhibit IL-17 homodimer and heterodimer. Based on the date of the priority data, the expected expiration date of this patent is at least until 2032. The related European Patent has already been granted in 2016.

“The delivery of this US Patent is a significant milestone for OREGA Biotech’s IL-17 program. Our business model relies on our ability to discover novel targets and to generate IP rights over targets or broad claims such as functional epitopes”, commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech. 

As of today, the patent portfolio of the company is composed of 9 families of patent applications owned or co-owned by OREGA biotech.

Read the press release.

L’article PRESS RELEASE – IL-17 patent to be granted in the US est apparu en premier sur Orega Biotech.

OREGA Biotech strengthens its intellectual property

OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced today that it has received a notification from the European Patent Office (EPO) stating its intention to grant a patent application filed by OREGA Biotech and related to novel anti-IL-17 antibodies. This patent covers any antibody binding to a functional epitope of IL-17 identified by OREGA Biotech and protects several specific neutralizing antibodies able to bind and inhibit IL-17 homodimer and heterodimer. Based on the date of the priority data, the expected expiration date of this patent is at least until 2032. This notification shortly follows another notice of allowance from the EPO which is about to deliver another strategic patent application held by INSERM and licensed to OREGA Biotech relating to antibodies that bind CD39.

As of today, the patent portfolio of the company is composed of 8 families of patent applications owned or co-owned by OREGA biotech and one licensed patent.

Read the press release.

L’article PRESS RELEASE – OREGA strengthens its intellectual property in Europe est apparu en premier sur Orega Biotech.